Enhancement of Apo2L/TRAIL (tumor necrosis factor–related apoptosis-inducing ligand)–induced apoptosis in non–small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein
- 1 January 2002
- journal article
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 123 (1) , 168-174
- https://doi.org/10.1067/mtc.2002.119694
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis SystemsExperimental Cell Research, 2000
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivoNature Medicine, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- TRAIL: a molecule with multiple receptors and control mechanismsCurrent Opinion in Immunology, 1998
- Apoptosis by Death FactorCell, 1997
- Combined-Modality Therapy for Unresectable, Stage III Non-Small-Cell Lung Cancer--Caveat Emptor or Caveat Venditor?JNCI Journal of the National Cancer Institute, 1996
- Identification and characterization of a new member of the TNF family that induces apoptosisImmunity, 1995
- Lethal effect of the anti-Fas antibody in miceNature, 1993
- The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity.The Journal of Experimental Medicine, 1988